Prophase Labs Inc's fundamentals are relatively weak, and its growth potential is good.Its valuation is considered fairly valued, ranking 67 out of 78 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 16.00.In the medium term, the stock price is expected to trend down.Despite a strong stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current strong trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prophase Labs Inc's Score
Industry at a Glance
Industry Ranking
67 / 78
Overall Ranking
479 / 4550
Industry
Healthcare Providers & Services
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Prophase Labs Inc Highlights
StrengthsRisks
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.77M.
Overvalued
The company’s latest PE is -0.02, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 303.07K shares, decreasing 50.33% quarter-over-quarter.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.